EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?

被引：82
作者：
Ke, E-E [1 ,2 ]
Wu, Yi-Long [1 ,2 ]
机构：
[1] Guangdong Acad Med Sci, Guangdong Lung Canc Inst, 106 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, Guangdong Gen Hosp, 106 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China
来源：
TRENDS IN PHARMACOLOGICAL SCIENCES | 2016年 / 37卷 / 11期
关键词：
GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITORS; CIRCULATING TUMOR DNA; PHASE-II TRIAL; OPEN-LABEL; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; BRAIN METASTASES; C797S MUTATION; ASIAN PATIENTS;
D O I：
10.1016/j.tips.2016.09.003
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Targeting the epidermal growth factor receptor (EGFR) using tyrosine kinase inhibitors (TKIs) is highly effective in terms of tumor response rate, survival, and quality of life. However, acquired resistance to EGFR-TKIs is inevitable. Ongoing clinical trials will provide evidence for optimal strategies for patients with EGFR mutant non-small-cell lung cancer (NSCLC) in the near future. Numerous new agents are specifically addressing resistance mechanisms; mature data are related to the T790M mutation and MET pathway activation. Here, we provide a comprehensive review of new perspectives on how to optimize the management of this molecular disease.
引用
收藏
页码：887 / 903
页数：17
相关论文
共 50 条
  • [41] Real-World Data on Prognostic Factors for Overall Survival in EGFR-Mutant Non-Small-Cell Lung Cancer Patients with Brain Metastases
    Yu, Xiaoqing
    Fan, Yun
    JOURNAL OF CANCER, 2019, 10 (15): : 3486 - 3493
  • [42] Therapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer
    Loong, Herbert H.
    Kwan, Sui-chun Sampson
    Mok, Tony Shu-kam
    Lau, Yat-ming
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2018, 19 (11)
  • [43] Continuation of osimertinib in EGFR-mutant non-small-cell lung cancer patients bearing CNS metastasis (EPONA study)
    Okuma, Yusuke
    Nomura, Shogo
    Ninomiya, Kiichiro
    Gyotoku, Hiroshi
    Murakami, Shuji
    Kogure, Yoshihito
    Harada, Daijiro
    Okishio, Kyoichi
    Okamoto, Hiroaki
    Goto, Yasushi
    FUTURE ONCOLOGY, 2023, : 1515 - 1521
  • [44] Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib
    Patel, Suchit H.
    Rimner, Andreas
    Foster, Amanda
    Zhang, Zhigang
    Woo, Kaitlin M.
    Yu, Helena A.
    Riely, Gregory J.
    Wu, Abraham J.
    LUNG CANCER, 2017, 108 : 109 - 114
  • [45] Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects
    Shi, Chunyan
    Wang, Yan
    Xue, Jianxin
    Zhou, Xiaojuan
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [46] Influence of TP53 Mutation on Survival in Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer
    Aggarwal, Charu
    Davis, Christiana W.
    Mick, Rosemarie
    Thompson, Jeffrey C.
    Ahmed, Saman
    Jeffries, Seth
    Bagley, Stephen
    Gabriel, Peter
    Evans, Tracey L.
    Bauml, Joshua M.
    Ciunci, Christine
    Alley, Evan
    Morrissette, Jennifer J. D.
    Cohen, Roger B.
    Carpenter, Erica L.
    Langer, Corey J.
    JCO PRECISION ONCOLOGY, 2018, 2 : 1 - 29
  • [47] Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines
    Dal Maso, Alessandro
    Lorenzi, Martina
    Ferro, Alessandra
    Pilotto, Sara
    Cecere, Fabiana
    Follador, Alessandro
    Polo, Valentina
    Del Conte, Alessandro
    Sartori, Giulia
    Giavarra, Marco
    Scattolin, Daniela
    Indraccolo, Stefano
    Frega, Stefano
    De Maglio, Giovanna
    Menis, Jessica
    Bonanno, Laura
    Calabrese, Fiorella
    Guarneri, Valentina
    Conte, PierFranco
    Pasello, Giulia
    FUTURE ONCOLOGY, 2021, 17 (19) : 2513 - 2527
  • [48] Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer
    Rossi, Sabrina
    Finocchiaro, Giovanna
    Di Noia, Vincenzo
    Bonomi, Maria
    Cerchiaro, Eleonora
    De Rose, Fiorenza
    Franceschini, Davide
    Navarria, Pierina
    Ceresoli, Giovanni Luca
    Beretta, Giordano Domenico
    D'Argento, Ettore
    Scorsetti, Marta
    Santoro, Armando
    Toschi, Luca
    FUTURE ONCOLOGY, 2019, 15 (33) : 3775 - 3782
  • [49] EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer
    Fang, Shu
    Wang, Zhehai
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2014, 8 : 1595 - 1611
  • [50] Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer
    Kawamura, Takahisa
    Kenmotsu, Hirotsugu
    Omori, Shota
    Nakashima, Kazuhisa
    Wakuda, Kazushige
    Ono, Akira
    Naito, Tateaki
    Murakami, Haruyasu
    Omae, Katsuhiro
    Mori, Keita
    Tanigawara, Yusuke
    Nakajima, Takashi
    Ohde, Yasuhisa
    Endo, Masahiro
    Takahashi, Toshiaki
    CLINICAL LUNG CANCER, 2018, 19 (02) : E247 - E252
12345